Genmab — Oktober 2020
-
-Maybe I can take the question on the EGFR-cMet antibody amivantamab. It is a really exciting project for us. You asked about near-term and long-term. First on the antibody itself, it's a really interesting antibody. It's unique to us and it incorporates both EGFR binding peak and the CMS binding peak and CMS is common resistance mechanism for EGFR therapy. So it's both the primary mutation and the resistance mechanism at the same time.
-
The near-term plan is to go forward with an Exon 20 EGFR tumor, non-small cell lung cancer, there are really no good opportunities for patients with Exon 20 signatures. But that's how we will begin but our eyes are on the larger EGFR mutation market and patients in non-small lung cancer. So with time, we plan on exploring multiple lines of therapy and eventually all EGFR containing tumors."
-
-
Meget informativt om Amivantamab. 6-12 md approval...moving to 1.line... Beklager hvis den har været linket. https://www.docwirenews.com/hematology-oncology/amivantamab-plus-lazertinib-combo-show-promising-results-at-esmo-2020/
-
SITC ID: 561
DuoBody
-PD-L1×4-1BB (GEN1046) induces superior immune-cell activation, cytokine production and cytotoxicity by combining PD-L1 blockade with conditional 4-1BB co-stimulation https://sitc.planion.com/Web.User/AbstractDet?ACCOUNT=SITC&ABSID=13906&CONF=SITC20&ssoOverride=OFF&CKEY= -
Thanks E L and bongobob
-
SITC ID: 412
First-in-human phase I/IIa trial to evaluate the safety and initial clinical activity of DuoBody-PD-L1×4-1BB (GEN1046) in patients with advanced solid tumors https://sitc.planion.com/Web.User/AbstractDet?ACCOUNT=SITC&ABSID=13347&CONF=SITC20&ssoOverride=OFF&CKEY= -
12:40 I like the phrase “superior”
-
Conclusions DuoBody-PD-L1×4-1BB demonstrated biologic activity and a manageable safety profile. Encouraging early clinical activity across different dose levels was observed in a heavily pretreated population with advanced solid tumors, including those resistant to prior immunotherapy or typically less sensitive to ICIs. Expansion cohorts of patients for whom DuoBody-PD-L1×4-1BB treatment could be relevant and biologically sound have started enrollment. Updated data will be presented.
-
SITC ID: 704
Preclinical mechanism of action and pharmacodynamic biomarker studies of DuoBody-CD3x5T4 in vitro and in vivo in solid cancer models https://sitc.planion.com/Web.User/AbstractDet?ACCOUNT=SITC&ABSID=13592&CONF=SITC20&ssoOverride=OFF&CKEY= -
Opdaterede salgstal på Darzalex. https://www.proinvestor.com/boards/87573#87574
-
SITC ID: 617
Tisotumab vedotin shows immunomodulatory activity through induction of immunogenic cell death https://sitc.planion.com/Web.User/AbstractDet?ACCOUNT=SITC&ABSID=13984&CONF=SITC20&ssoOverride=OFF&CKEY=
Hello! It looks like you're interested in this conversation, but you don't have an account yet.
Getting fed up of having to scroll through the same posts each visit? When you register for an account, you'll always come back to exactly where you were before, and choose to be notified of new replies (either via email, or push notification). You'll also be able to save bookmarks and upvote posts to show your appreciation to other community members.
With your input, this post could be even better 💗
Tilmeld Log ind